The invention relates to a foam formulation comprising an emulsion, comprising an oil phase and an aqueous phase, wherein the emulsion comprises at least one triterpenoid. Further the invention relates to an emulsion comprising an oil phase and an aqueous phase, wherein the emulsion comprises at least one triterpenoid selected from the group consisting of betulin, betulinic acid, lupeol, erythrodiol, oleanolic acid, (C.sub.1-C.sub.6) alkyl esters of the aforementioned acids, or mixtures thereof, and wherein the oil phase comprises at least one membrane-forming substance forming a lamellar arranged membrane in the emulsion.

The disclosure teaches the use of antistatic materials in the airway for thermal aerosol generation devices. The present disclosure teaches the use of antistatic materials for drug delivery in any drug that may be susceptible to charging during aerosol generation.

The disclosure teaches the use of antistatic materials in the airway for thermal aerosol generation devices. The present disclosure teaches the use of antistatic materials for drug delivery in any drug that may be susceptible to charging during aerosol generation.

The discovery of mutant or fusion kinases that drive oncogenesis, and the subsequent approval of specific inhibitors for these enzymes, has been instrumental in the management of some cancers. However, acquired resistance remains a significant problem in the clinic, limiting the long-term effectiveness of most of these drugs. Herein is demonstrated a strategy to overcome this resistance through drug-induced MEK cleavage (via direct procaspase-3 activation) combined with targeted kinase inhibition. This combination effect is shown to be general across diverse tumor histologies (melanoma, lung cancer, and leukemia) and driver mutations (mutant BRAF or EGFR, fusion kinases EML4-ALK and BCR-ABL). Caspase-3-mediated degradation of MEK kinases results in sustained pathway inhibition and substantially delayed or eliminated resistance in cancer cells in a manner superior to combinations with MEK inhibitors. These data suggest the generality of drug-mediated MEK kinase cleavage as a therapeutic strategy to prevent resistance to targeted anticancer therapies.

Substrates for use with an aerosol delivery device to vaporize and deliver an aerosol to a user include a base material, an aerosol former and an aerosol agent. In a method for forming the substrates, a mixture of substrate materials is extruded and then spheronized to produce pellet substrates that are generally spherical, substantially spherical or rounded, or in the form of relatively short rods having rounded ends. In another method for forming the substrates, a base material is coated with a first coating and optionally the base material having the first coating thereon is subsequently coated with a second coating so as to produce pellet substrates having a relatively smooth, dry exterior surface. In this manner, the substrates are formable relative to one another and can be easily and readily loaded into and removed from the aerosol delivery device.

The present invention relates to a skin topical composition having an antipruritic efficacy, comprising a combination of (A) birch sap and (B) betaine, and the skin topical composition does not comprise water added as a separate component. The skin topical composition is a pharmaceutical composition or a cosmetic composition.

Compositions and devices comprising apomorphine or pharmaceutically acceptable salts are described. The compositions may comprise a solution of apomorphine, or a pharmaceutically acceptable salt thereof, and a propellant. The solution may be a non-aqueous solution or an aqueous solution comprising degassed water. Devices may be configured to deliver compositions in form of particles or droplets having a mass median aerodynamic diameter (MMAD) or volume median diameter (VMD) greater than 10 pm; and/or a fine particle fraction (FRF) less than 30%.

Provided herein is the conjugation of an amanita toxin compound to a cell-binding molecule with branched linkers for having better targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of an amanita molecule to a cell-binding ligand, as well as methods of using the conjugate in targets treatment of cancer, infection and autoimmune disease.

A pressurized medicinal composition comprising at least 40%, by weight, of liquid carbon dioxide, a fluid that forms a homogeneous solution with liquid carbon dioxide, and at least one active pharmaceutical ingredient dissolved or suspended in the composition. The composition may have a liquid to supercritical transition temperature greater than 40° C. Also, metered dose inhalers comprising an actuator, and a canister equipped with a metering valve, wherein the canister houses a reservoir comprising a pressurized carrier fluid mixture for dissolving or suspending at least one active pharmaceutical ingredient, the carrier fluid mixture comprising liquid carbon dioxide and a second component that is a liquid at room temperature and pressure.

A pressurized medicinal composition comprising at least 40%, by weight, of liquid carbon dioxide, a fluid that forms a homogeneous solution with liquid carbon dioxide, and at least one active pharmaceutical ingredient dissolved or suspended in the composition. The composition may have a liquid to supercritical transition temperature greater than 40° C. Also, metered dose inhalers comprising an actuator, and a canister equipped with a metering valve, wherein the canister houses a reservoir comprising a pressurized carrier fluid mixture for dissolving or suspending at least one active pharmaceutical ingredient, the carrier fluid mixture comprising liquid carbon dioxide and a second component that is a liquid at room temperature and pressure.